Appili Therapeutics Inc continues to tread water, with no major price movement this week amid limited news.
Appili Therapeutics Inc (APLI.TO) has experienced stagnant price action recently, closing at C$0.01 with no change day-over-day. The stock has seen a significant decline of 60% year-to-date and a 33.33% drop over the past month. Investors are watching closely as the company navigates its operational and financial landscape.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
266.4%
Annualized
90-Day Vol
252.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.03 |
| 90 trading days | C$0.01 | C$0.00 – C$0.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite the lack of significant upward movement in the stock price, Appili has reported progress in its operational initiatives and secured funding, which may be a positive sign for long-term investors. However, the company's stock remains in a precarious position given its historical performance.
Appili's Stock Stagnates at C$0.01 with Significant Year-to-Date Decline
The stock's performance reflects a challenging operational environment, with a staggering 60% drop in value since the beginning of the year, warranting caution among investors.
Bull case
Recent announcements about funding and operational advancements are encouraging. U.S. federal funding proposals could provide a much-needed boost to the company, creating a more optimistic outlook for investors.
Bear case
On the flip side, the significant decline in stock value and ongoing financial struggles raise concerns about Appili's ability to sustain operations and achieve profitability.
Current Price Action
Appili Therapeutics Inc's stock closed at C$0.01 this week, reflecting no change in price from the previous day. Over the past month, the stock has declined by 33.33%, and year-to-date, it has dropped a staggering 60%. This stagnant performance highlights the challenges the company faces in the current market environment.
Recent Company News
Advertisement
While there were no major announcements this week, Appili Therapeutics has recently reported its fiscal year 2026 financial and operational results. The company highlighted progress in its commercial-stage programs and secured non-dilutive funding, which may bolster its future endeavors. Additionally, there were reports of a definitive agreement for Aditxt to acquire Appili, aiming to enhance its biodefense vaccine programs.
Technical Picture
From a technical standpoint, Appili's stock is trading below both its 50-day moving average of C$0.01 and its 200-day moving average of C$0.02. The stock's 52-week range has been between C$0.01 and C$0.04, indicating that it is currently at the lower end of this spectrum. The stock has a beta of -0.20, suggesting it is less volatile compared to the overall market. The recent trading volume of 207,000 shares is 1.25 times the 20-day average volume of 77,267 shares, indicating increased interest or activity.
Insider Activity
No insider activity has been reported recently, which may suggest a lack of confidence or significant developments from internal stakeholders.
Price Action Summary
Appili Therapeutics Inc's stock closed at C$0.01, unchanged from the previous day, reflecting ongoing challenges in the market. Investors remain cautious as the company continues to navigate its financial landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
